title: The impact of rosiglitazone on nitric oxide bioavailability and endothelial function.
abstract: Clinical studies have demonstrated that rosiglitazone can improve vascular function in patients with diabetes mellitus. It remains unclear whether this effect depends on a direct improvement in endothelial function or whether it is mediated by the drug's effect on glycemic control. Yet, rosiglitazone has been linked to serious cardiovascular events. A number of studies recently investigated whether rosiglitazone affects endothelial function in healthy volunteers and patients with cardiovascular disease. Controversial observations have been reported; the observation that rosiglitazone might in certain cases impair endothelial function may suggest a mechanistic explanation for the observation of increased cardiovascular events in patients treated with rosiglitazone who have underlying cardiovascular disease. These studies are summarized and discussed in the present paper.
authors.affiliation: Division of Cardiology, Mount Sinai and University Health Network Hospitals, University of Toronto, Toronto, Canada.
authors.forename: Kumar
authors.initials: K
authors.lastname: Perampaladas
authors.forename: John D
authors.initials: JD
authors.lastname: Parker
authors.forename: Tommaso
authors.initials: T
authors.lastname: Gori
mesh_terms: D003920:Diabetes Mellitus; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D009569:Nitric Oxide / Q000096:biosynthesis*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000009:adverse effects / Q000494:pharmacology*; D014665:Vasodilator Agents
chemical_list: D045162:Thiazolidinediones; D014665:Vasodilator Agents; D000077154:Rosiglitazone; D009569:Nitric Oxide